Protalix BioTherapeutics (PLX) Cash & Equivalents (2010 - 2026)
Protalix BioTherapeutics' quarterly Cash & Equivalents came in at $711000.0 in Q1 2026, down 96.35% year-on-year from $19.5 million in Q1 2025, and up 1.28% quarter-over-quarter from $702000.0 in Q4 2025.
Protalix BioTherapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $711000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 96.35% year-over-year to $711000.0; the trailing twelve-month figure through Mar 2026 stood at $711000.0 (down 96.35% YoY), and the FY2025 full-year result was $702000.0, changed N/A from the prior year.
- Cash & Equivalents for Q1 2026 stood at $711000.0, up from $702000.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $48.2 million in Q2 2023, with the low at $702000.0 in Q4 2025.
- Average Cash & Equivalents over 5 years is $19.6 million, with a median of $18.7 million recorded in 2025.
- Year-over-year, Cash & Equivalents surged 285.72% in 2023 and sank 96.35% in 2026.
- Tracing PLX's Cash & Equivalents over 5 years: stood at $17.1 million in 2022, then surged by 38.12% to $23.6 million in 2023, then grew by 15.97% to $27.4 million in 2024, then slumped by 97.44% to $702000.0 in 2025, then advanced by 1.28% to $711000.0 in 2026.
- The last three Cash & Equivalents figures came in at $711000.0 (Q1 2026), $702000.0 (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 711,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 711,000.00 |
| Dec 31, 2025 | 702,000.00 |
| Sep 30, 2025 | 13.65 Mn |
| Jun 30, 2025 | 17.90 Mn |
| Mar 31, 2025 | 19.46 Mn |
| Sep 30, 2024 | 27.41 Mn |
| Jun 30, 2024 | 23.40 Mn |
| Mar 31, 2024 | 27.21 Mn |
| Dec 31, 2023 | 23.63 Mn |
| Sep 30, 2023 | 20.41 Mn |
| Jun 30, 2023 | 48.18 Mn |
| Mar 31, 2023 | 33.04 Mn |
| Dec 31, 2022 | 17.11 Mn |
| Sep 30, 2022 | 10.72 Mn |
| Jun 30, 2022 | 12.49 Mn |
| Mar 31, 2022 | 16.89 Mn |
| Dec 31, 2021 | 38.99 Mn |
| Sep 30, 2021 | 10.64 Mn |
| Jun 30, 2021 | 33.88 Mn |
| Mar 31, 2021 | 19.83 Mn |
| Dec 31, 2020 | 436,000.00 |
| Sep 30, 2020 | 13.53 Mn |
| Jun 30, 2020 | 4.84 Mn |
| Mar 31, 2020 | 14.17 Mn |
| Dec 31, 2019 | 17.79 Mn |
| Sep 30, 2019 | 21.44 Mn |
| Jun 30, 2019 | 25.10 Mn |
| Mar 31, 2019 | 30.36 Mn |
| Dec 31, 2018 | 37.81 Mn |
| Sep 30, 2018 | 41.87 Mn |
| Jun 30, 2018 | 28.33 Mn |
| Mar 31, 2018 | 41.32 Mn |
| Dec 31, 2017 | 51.16 Mn |
| Sep 30, 2017 | 33.48 Mn |
| Jun 30, 2017 | 34.53 Mn |
| Mar 31, 2017 | 48.02 Mn |
| Dec 31, 2016 | 63.28 Mn |
| Sep 30, 2016 | 51.32 Mn |
| Jun 30, 2016 | 54.63 Mn |
| Mar 31, 2016 | 66.67 Mn |
| Dec 31, 2015 | 76.37 Mn |
| Sep 30, 2015 | 34.25 Mn |
| Jun 30, 2015 | 43.24 Mn |
| Mar 31, 2015 | 47.96 Mn |
| Dec 31, 2014 | 54.77 Mn |
| Mar 31, 2014 | 77.69 Mn |
| Dec 31, 2013 | 86.40 Mn |
| Sep 30, 2013 | 91.40 Mn |
| Jun 30, 2013 | 33.13 Mn |
| Mar 31, 2013 | 41.87 Mn |
| Dec 31, 2012 | 52.04 Mn |
| Sep 30, 2012 | 50.22 Mn |
| Jun 30, 2012 | 59.28 Mn |
| Mar 31, 2012 | 45.61 Mn |
| Dec 31, 2011 | 27.00 Mn |
| Sep 30, 2011 | 34.56 Mn |
| Jun 30, 2011 | 44.05 Mn |
| Mar 31, 2011 | 50.23 Mn |
| Dec 31, 2010 | 35.90 Mn |
| Sep 30, 2010 | 44.40 Mn |
| Jun 30, 2010 | 54.96 Mn |